Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $61.2352W HIGH $116.84
Volume
49.77 K
Value Traded
506.63 M
Short % Float
13.5%
-0.02%Week
+2.28%1 Month
+44.15%3 Month
+61.96%6 Month
+57.75%5 Year
+1,721.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.54 B
EPS (TTM)
3.64
P/E Ratio
30.14
Ent. Value
14.38 B
Total Shares
113.50 M
Float Shares
112.27 M
Insiders
1.09%
Institutions
110.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HALO Catalyst Timeline
Dated clinical, regulatory and corporate events for Halozyme Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Halozyme Therapeutics, Inc.
1134Total events
10Upcoming
387Tier-1 (high impact)
2010 to 2033Coverage
Upcoming catalysts 2
Event history 50
▲IP Litigation RulingIP / Competition
Dutch court finds Merck infringes Halozyme EP622 MDASE patent and grants injunction against Keytruda SC in eight European markets
▲Partnership / LicenseCorporate
Halozyme expands global collaboration and license agreement with argenx to add two additional exclusive ENHANZE targets
●Debt Royalty FinancingCorporate
Repurchase of 2027 and 2028 convertible notes concurrently with pricing
◆Equity OfferingCorporate
Proposed offering of $1.05 billion convertible senior notes due 2033
●Debt Royalty FinancingCorporate
Privately negotiated repurchases of 2027 and 2028 Existing Convertible Notes
▲Partnership / LicenseCorporate
Global collaboration and license agreement with Incyte for ENHANZE technology with INCA033989
▲Timing GuidancePresentation
Halozyme projects zero to minimal royalty revenue impact through at least 2035 based on CMS proposed rule
▲Topline ReadoutClinical Data
Positive Phase 3 data in ocular myasthenia gravis
ocular myasthenia gravissource ↗
▲Topline ReadoutTAK-881Clinical Data
Positive Phase 2/3 data for TAK-881 in primary immune deficiency
primary immune deficiencysource ↗
▲Equity OfferingCorporate
Announced new $1 billion share repurchase program, projecting at least $400 million in 2026
▲Partnership / LicenseCorporate
Halozyme enters global collaboration and license agreement with GSK for ENHANZE technology in multiple oncology targets including ADCs
oncologysource ↗
▲Partnership / LicenseCorporate
Halozyme and Oruka announce global collaboration and license agreement for Hypercon technology with ORKA-001
▲Partnership / LicenseCorporate
Global exclusive collaboration and license agreement with Vertex for Hypercon technology
◆Trial InitiationnimacimabTrial
Initiation of Phase 2b clinical trial for nimacimab with ENHANZE
obesitysource ↗
◆Management ChangeCorporate
CFO Nicole LaBrosse to depart by March 30, 2026; external search initiated
◆Quarterly UpdateCorporate
Investor Conference Call to provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and business update
●Oral PresentationPresentation
Investor conference call to discuss business update and financial guidance
▲Partnership / LicenseCorporate
New collaboration and licensing agreements with Vertex, Oruka and GSK
▲Quarterly UpdateCorporate
Preliminary unaudited 2025 total revenue $1,385-$1,400M, royalty revenue $865-$870M
▲Full ResultsClinical Data
PALOMA-3 results meeting co-primary PK endpoints
EGFR-mutated advanced NSCLCsource ↗
▲IP Litigation RulingIP / Competition
German court granted Halozyme preliminary injunction stopping Merck's launch of Keytruda SC in Germany
◆Oral PresentationPresentation
Halozyme presentation at 8th Annual Evercore Healthcare Conference
▲Full ResultsTECVAYLIClinical Data
Phase 3 MajesTEC-3 results presented at ASH 2025
relapsed or refractory multiple myelomasource ↗
▲Partnership / LicenseCorporate
Global collaboration and exclusive license agreement with Takeda for ENHANZE technology with vedolizumab
▲Partnership / LicenseENHANZEFiledCorporate
Global collaboration and license agreement for nimacimab co-formulated with ENHANZE
obesitysource ↗
▲IP Litigation RulingIP / Competition
German Court Granted Preliminary Injunction Against Merck for Keytruda SC Distribution
▲Partnership / LicensepetosemtamabCorporate
Merus and Halozyme enter global collaboration to develop subcutaneous formulation of petosemtamab using ENHANZE technology
solid tumors; head and neck cancersource ↗
▼Equity OfferingCorporate
Pricing of $650M 0% convertible senior notes due 2031 and $650M 0.875% convertible senior notes due 2032
▲Quarterly UpdateCorporate
Halozyme reports Q3 2025 financial results and raises 2025 guidance
▲Partnership / LicenseCorporate
Entered Collaboration with Merus for petosemtamab SC using ENHANZE
◆AcquisitionCorporate
Halozyme to acquire Elektrofi for $750M upfront plus up to $150M in milestones
Past FDA Catalysts and PDUFA Decisions
How HALO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-30 | Opdivo® (nivolumab) co-formulated with ENHANZE® | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$0M
Pipeline Value
$6.9B
Commercial Value
Overvalued
Valuation Signal
22
Drugs Scored
-
rNPV / MCap
Top 77%
Mid Cap(rank 507 of 658)
Percentile Rank
Halozyme Therapeutics, Inc. faces pipeline headwinds (27/100), with 22 assets in development.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $1.7B x 4.2 = $6.9B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Bulk rHuPH20 | $216M | $101M | +112.7% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Xyosted Small moleculeNCT06689085 | Hypogonadism, Male | Phase 3 | RECRUITING | 100 | Mar 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every HALO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| nivolumab | advanced or metastatic clear cell renal cell carcinoma | Phase 3 | 2023-10-19 | A total of 495 patients were randomized to either subcutaneous nivolumab or intravenous Opdivo.Read More | Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( Halozyme ) today announced that Bristol Myers Squibb (BMS) reported positive topline results from the...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Torley HelenDirector, Officer (PRESIDENT AND CEO) | Option | 20,000 787,780 held | $18.41 | 10/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HALO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 0.5 % | 15.76 M | 392.00 K |
HALO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HALO ranks across every disease it competes in
Competitive Position is a premium feature
See how HALO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHALO News
HALO▲ +0.7%today
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
Halozyme Therapeutics has secured a Dutch court injunction against Merck, preventing the manufacture and sale of Keytruda SC in several European countries due to patent infringement. The court upheld the validity of Halozyme's MDASE patent, which is crucial for subcutaneous drug delivery. Patients will still have access to the intravenous version of Keytruda.
Read more →HALO▲ +0.7%today
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Halozyme Therapeutics has expanded its collaboration with argenx, increasing the number of exclusive targets for the ENHANZE technology from six to eight. This move aims to enhance patient convenience through subcutaneous drug delivery. The partnership is expected to strengthen Halozyme's portfolio and offers potential long-term opportunities across various therapeutic areas.
Read more →HALOHalozyme Announces Appointment of Jim Daly to its Board of Directors
Halozyme Therapeutics has appointed Jim Daly to its Board of Directors. Daly, a seasoned biopharmaceutical executive, has over 30 years of experience in commercial leadership. His past roles include significant positions at Incyte and Amgen. The company anticipates that his expertise will aid in the growth of its subcutaneous delivery technologies.
Read more →HALOHalozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics has announced the pricing of an upsized private offering of $1.3 billion in convertible senior notes due 2033. The offering was increased from an initial $1.05 billion, and includes a 13-day option for initial purchasers to buy an additional $200 million. The proceeds will be used for various corporate purposes, including repurchasing existing convertible notes.
Read more →HALOHalozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Halozyme Therapeutics, Inc. has announced a proposed offering of $1.05 billion in convertible senior notes due in 2033. The offering aims to provide financial flexibility for the company, with a portion of the proceeds allocated for capped call transactions and repurchases of existing convertible notes. The notes will be offered only to qualified institutional buyers, and their terms will be finalized during pricing negotiations.
Read more →HALOHalozyme to Participate at Upcoming Investor Conferences
Halozyme Therapeutics will participate in several upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Dr. Helen Torley and CFO Darren Snellgrove will host investor meetings and present at these events. The company continues to highlight its advancements in drug delivery technologies.
Read more →HALOHalozyme Appoints Dannielle Appelhans to its Board of Directors
Halozyme Therapeutics has appointed Dannielle Appelhans to its Board of Directors. With over 20 years of experience in the biotechnology sector, Appelhans is expected to enhance Halozyme's growth strategy, particularly in operations and manufacturing. Her previous leadership roles and successful collaborations will be valuable as Halozyme continues to advance its drug delivery technologies.
Read more →HALO▲ +20.2%on this news
Halozyme Reports Record Second Quarter 2026 Results, Beats Estimates And Raises Full Year 2026 Financial Guidance
Halozyme Therapeutics reported a strong second quarter for 2026, with total revenue rising 48% year-over-year to $481 million, driven by a 50% increase in royalty revenue. The company raised its full-year financial guidance, anticipating total revenue between $1.835 billion and $1.910 billion. Additionally, Halozyme signed five new collaboration agreements, exceeding its goal for the year. However, increased operational costs and ongoing litigation may pose challenges.
Read more →HALOHalozyme to Report Second Quarter 2026 Financial and Operating Results
Halozyme Therapeutics, Inc. will announce its second quarter 2026 financial results on August 6, 2026. A conference call will follow the announcement to discuss the results. The company continues to advance its innovative drug delivery technologies, including ENHANZE®, which has significantly improved patient experiences.
Read more →HALOHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Halozyme Therapeutics has entered a global collaboration with Incyte to develop subcutaneous formulations of INCA033989 using its ENHANZE technology. This partnership aims to enhance treatment delivery for patients with mutCALR-expressing myeloproliferative neoplasms. Halozyme will receive an upfront payment and potential royalties, while Incyte can nominate additional targets for development.
Read more →HALOHalozyme Appoints David Ramsay as President Drug Delivery
Halozyme Therapeutics has appointed David Ramsay as President of Drug Delivery, effective June 30, 2026. In this newly created position, Ramsay will oversee the growth of the company's drug delivery technologies. He brings over 30 years of experience in financial leadership within the biotechnology sector, having previously served as Halozyme's CFO. Ramsay aims to enhance value creation for shareholders through strategic initiatives.
Read more →HALOHalozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Halozyme Therapeutics has confirmed that it anticipates zero to minimal impact on its royalty revenues through at least 2035, following an analysis of the proposed Medicare Drug Price Negotiation Program rule. The company remains optimistic about its ENHANZE partnership agreements and the continued applicability of orphan drug protections. Halozyme aims to engage with CMS to support favorable policies for innovation and patient access.
Read more →HALO▲ +6.8%on this news
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics reported a strong financial performance for Q1 2026, with a 42% increase in total revenue to $377 million. The company announced a $1 billion share repurchase program and reiterated its 2026 financial guidance, projecting total revenue between $1.710 billion and $1.810 billion. Recent collaborations with Vertex, Oruka, and GSK highlight the growing interest in Halozyme's drug delivery technologies.
Read more →HALOHalozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Halozyme Therapeutics has entered a global collaboration with GSK to develop subcutaneous formulations for multiple oncology targets, including antibody drug conjugates. This agreement marks the first use of Halozyme's ENHANZE technology for ADCs, aiming to enhance patient treatment experiences. The first clinical trial is expected to begin in 2026, with potential royalties for Halozyme from future sales.
Read more →HALOHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology Halozyme Therapeutics, Inc. (Nasdaq: HALO) ( Halozyme ) and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ( Oruka ) today announced that Halozyme's...
Halozyme Therapeutics and Oruka Therapeutics have formed a global collaboration to develop ORKA-001 using Halozyme's Hypercon™ technology, focusing on psoriasis and related inflammatory diseases. The agreement grants Oruka exclusive rights to utilize Halozyme's microparticle technology, which enhances drug delivery by reducing injection volume. Oruka will make an upfront payment and potential milestone payments to Halozyme, which will also receive royalties on sales. This partnership marks a significant step toward improving treatment options for patients with chronic skin conditions.
Read more →HALOHalozyme Appoints Darren Snellgrove as Chief Financial Officer
Halozyme Therapeutics has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove, who has over 30 years of experience in financial leadership, will oversee financial operations and strategy. His previous role at Johnson & Johnson involved reshaping investor relations and corporate messaging. This appointment is seen as a strategic move to drive growth and shareholder value.
Read more →HALOHalozyme to Report First Quarter 2026 Financial and Operating Results
Halozyme Therapeutics, Inc. will release its first quarter 2026 financial and operating results on May 11, 2026. A conference call will follow the results announcement, allowing stakeholders to discuss the outcomes. The company continues to innovate in drug delivery technologies, enhancing patient experiences and outcomes.
Read more →HALOHalozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
Halozyme Therapeutics has entered a global collaboration with Vertex Pharmaceuticals to license its Hypercon technology, which allows for hyperconcentration of drugs. This partnership aims to improve patient access to biologics by reducing injection volume and enabling at-home administration. Vertex will pay Halozyme $15 million upfront, with additional milestone payments and royalties on sales.
Read more →HALOHalozyme Appoints David Ramsay as Interim Chief Financial Officer
Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Ramsay, who has over 30 years of experience in financial leadership, previously served as CFO of Halozyme and played a significant role in the company's growth. The search for a permanent CFO is actively underway.
Read more →HALOU.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Halozyme Therapeutics announced that the FDA has approved TECVAYLI in combination with DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma. This approval is based on Phase 3 data showing significant improvements in progression-free survival and overall survival compared to standard treatments. The new regimen offers a convenient subcutaneous administration method for patients.
Read more →About Halozyme Therapeutics, Inc.
Headquarters12390 EL CAMINO REAL, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next HALO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime